EDN1 and focal segmental glomerulosclerosis: Importantly, chronic treatment with sparsentan preserved glomerular hemodynamics and GFB functions in FSGS, as well as ameliorated the strong effects of acute vasoconstrictor challenges with the 2 mechanistically and therapeutically relevant agonists (ET-1 and AngII).